title: Placebo-controlled comparison of piroxicam-beta-cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans.
abstract: The acute gastroduodenal mucosa injury and gastric potential difference (GPD) drops provoked by 14-day administration of 20 mg/day of a new piroxicam formulation (piroxicam-beta-cyclodextrin), 20 mg/day standard piroxicam and 100 mg/day indomethacin were evaluated and compared in a randomized, double-blind, placebo-controlled study carried out on 64 volunteers. Endoscopic examinations, performed after 14-day treatment, demonstrated that piroxicam-beta-cyclodextrin was less gastrolesive (mean endoscopic score +/- SE = 0.56 +/- 0.2) than either piroxicam (2.06 +/- 0.5) or indomethacin (2.25 +/- 0.5) (p < 0.01). The drop in GPD after a single dose of the assigned drug was considerably greater for piroxicam and indomethacin than for piroxicam-beta-cyclodextrin (p < 0.01), which registered similar values to placebo. Since GPD is an expression of the anatomo-functional integrity of the gastric barrier, the results indicate that piroxicam-beta-cyclodextrin exerts less direct acute damage on the gastric mucosa. Therefore, when administered short-term, piroxicam-beta-cyclodextrin appears to be less gastrolesive than either indomethacin or the standard piroxicam formulation.
authors: Istituto di Gastroenterologia ed Endoscopia Digestiva, University of Perugia, Italy.
authors: L
authors: L
authors: Santucci
authors: S
authors: S
authors: Fiorucci
authors: S
authors: S
authors: Chiucchiù
authors: A
authors: A
authors: Sicilia
authors: L
authors: L
authors: Bufalino
authors: A
authors: A
authors: Morelli
mesh_terms: D000328:Adult; D003505:Cyclodextrins / Q000009:adverse effects*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D005773:Gastroscopy; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D010894:Piroxicam / Q000009:adverse effects*; D047392:beta-Cyclodextrins
chemical_list: D003505:Cyclodextrins; D004338:Drug Combinations; D047392:beta-Cyclodextrins; D010894:Piroxicam; C061072:piroxicam-beta-cyclodextrin; D007213:Indomethacin